Jenny P. Ting, PhD, the William Kenan Professor of Genetics and Microbiology & Immunology has been elected to serve as vice president of the American Association of Immunologists for the 2019-2020 term. Ting has been an active member of the organization for since 1997. AAI is dedicated to advancing the field of immunology and fostering … Continued
The National Cancer Institute has awarded a five-year grant of more than $2.2 million to UNC Lineberger’s Yuliya Pylayeva-Gupta, PhD, to support her research into the immune response in pancreatic cancer, one of the deadliest cancers. “Understanding the role of immune regulation in pancreatic cancer represents a crucial stepping stone on our way to advancing … Continued
University of North Carolina Lineberger Comprehensive Cancer Center researchers presented innovative new strategies for using tiny particles – particles the size of a DNA molecule or the width of a human hair – to boost cancer treatment as part of the Carolina Center of Cancer Nanotechnology Excellence/National Cancer Institute site visit on Tuesday. The researchers, … Continued
The University of North Carolina System recently awarded UNC Lineberger’s Andrew Wang, MD, and Jonathan Serody, MD, a four year, $2.09 million Research Opportunities Initiative grant to support their research using pharmacoengineering approaches to develop more effective personalized cancer vaccines. The grant was one of 15 awarded to scientists across the UNC System, with the specific intent to support … Continued
At the 60th American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger’s Natalie Grover, MD, presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker.
UNC Lineberger researchers led by Blossom Damania, PhD, and Penny Anders, PhD, published a paper in the Journal of Clinical Investigation that explains how the viral protein vPK helps drive abnormal growth of immune cells called B cells. Their findings identify vPK as a potential druggable target to block or treat cancer in people infected with the virus.